1-3 of 3
Zhe Nie
Close
Sort by
Journal Articles

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies

Adam Olszewski, David Kahn, Brian Yoo, Joanne BL Tan, Vipul K Gupta, Edgar Schuck, Zhe Nie, Goran Krilov, D. Hamish Wright, Daniel Weiss, Jean Lachowicz, Karen Akinsanya, Wu Yin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3102.
https://doi.org/10.1182/blood-2023-182838
Published: 2023
Journal Articles

Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile

Wu Yin, Min Ye, Netonia Marshall, Joanne BL Tan, Evan Paull, Zhe Nie, MIchael Trzoss, Goran Krilov, Shulu Feng, Robert Pelletier, Jeff Bell, Peter Skrdla, David Calkins, MaryBeth Grimes, D. Hamish Wright, Karen Akinsanya
Journal: Blood
Blood (2023) 142 (Supplement 1): 2997.
https://doi.org/10.1182/blood-2023-190985
Published: 2023
Journal Articles

Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Wu Yin, Zhe Nie, Karen Dingley, Michael Trzoss, Goran Krilov, Netonia Marshall, Shulu Feng, Robert Pelletier, Jeff Bell, Paul Devine, Peter Skrdla, Roman Shimanovich, Min Ye, David Calkins, Mary Grimes, Wayne Tang, Andrew Placzek, Morgan Lawrenz, Fiona McRobb, Aleksey Gerasyuto, Victoria Feher, Sayan Mondal, Kristian Jensen, Hamish Wright, Daniel Weiss, Karen Akinsanya
Journal: Blood
Blood (2021) 138 (Supplement 1): 1187.
https://doi.org/10.1182/blood-2021-153159
Published: 2021